GE - GE: Notably Undervalued After Blockbuster Biopharma Deal
Source: Assemblymag.com
Notably Undervalued After Blockbuster Biopharma Deal
General Electric (GE) recently announced plans to sell its biopharma division to Danaher Corporation (DHR) in a deal valued at $21.4 billion. However, GE’s biopharma division is only accountable for about $3 billion in revenues, and the GE Healthcare business of which the biopharma division is a part of delivered nearly $20 billion in revenues last year.
Past appraisals of GE’s Healthcare unit ranged widely, with a Bloomberg intelligence analyst estimating its worth to be around $65-70 billion, I estimated the